On April 2, 2024 Kelonia Therapeutics, a biotech company revolutionizing in vivo gene delivery, reported new preclinical data from its lead program KLN-1010, which will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2024 in San Diego, California (Press release, Kelonia Therapeutics, APR 2, 2024, View Source [SID1234641724]). KLN-1010, a novel, in vivo CAR-T cell therapy candidate for the treatment of multiple myeloma, which leverages the company’s in vivo Gene Placement System (iGPS) technology, demonstrated that it is safe and effective in preclinical animal models.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These data reinforce the best-in-class potential of our in vivo CAR-T cell therapies," said Kevin Friedman, Ph.D., Chief Executive Officer and Founder of Kelonia. "By eliminating the need for ex vivo manufacturing and toxic lymphodepleting chemotherapy, we believe our iGPS technology will remove barriers that currently prevent patients from accessing transformative genetic medicines. We are excited by the preclinical profile of KLN-1010, and are looking forward to advancing this program towards the clinic in the near future."

Diverse T cell lineages, including memory and effector CD4 and CD8 T cells were modified in vivo by KLN-1010 to express a fully human anti-BCMA CAR, without detectable transduction of multiple myeloma tumor cells. A single intravenous injection of KLN-1010 displayed potent anti-tumor efficacy and caused complete tumor regression at multiple dose levels in several preclinical animal models. In other studies, treatment of non-human primates with an iGPS particle expressing an anti-CD20 CAR resulted in potent CAR-T cell activity lasting several months without the need for additional treatments or conditioning chemotherapy.

Details for the poster presentation are as follows:

Title: T cell-specific in vivo transduction with preclinical candidate KLN-1010 generates BCMA directed CAR T cells with potent anti-multiple myeloma activity
Poster Session: Adoptive Cell Therapies 2: CAR-T Cells
Date and Time: April 7, 2024 at 1:30-5:00 pm PT
Location: Section 2
Poster Number: 16